275 related articles for article (PubMed ID: 35158020)
1. The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy.
Jagannathan S
Biochim Biophys Acta Mol Basis Dis; 2022 May; 1868(5):166367. PubMed ID: 35158020
[TBL] [Abstract][Full Text] [Related]
2. A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy.
Feng Q; Snider L; Jagannathan S; Tawil R; van der Maarel SM; Tapscott SJ; Bradley RK
Elife; 2015 Jan; 4():. PubMed ID: 25564732
[TBL] [Abstract][Full Text] [Related]
3. Influence of
Duranti E; Villa C
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
[TBL] [Abstract][Full Text] [Related]
4. MATR3 is an endogenous inhibitor of DUX4 in FSHD muscular dystrophy.
Runfola V; Giambruno R; Caronni C; Pannese M; Andolfo A; Gabellini D
Cell Rep; 2023 Sep; 42(9):113120. PubMed ID: 37703175
[TBL] [Abstract][Full Text] [Related]
5. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
[TBL] [Abstract][Full Text] [Related]
6. Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.
Campbell AE; Belleville AE; Resnick R; Shadle SC; Tapscott SJ
Hum Mol Genet; 2018 Aug; 27(R2):R153-R162. PubMed ID: 29718206
[TBL] [Abstract][Full Text] [Related]
7. DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.
Yao Z; Snider L; Balog J; Lemmers RJ; Van Der Maarel SM; Tawil R; Tapscott SJ
Hum Mol Genet; 2014 Oct; 23(20):5342-52. PubMed ID: 24861551
[TBL] [Abstract][Full Text] [Related]
8. Direct interplay between two candidate genes in FSHD muscular dystrophy.
Ferri G; Huichalaf CH; Caccia R; Gabellini D
Hum Mol Genet; 2015 Mar; 24(5):1256-66. PubMed ID: 25326393
[TBL] [Abstract][Full Text] [Related]
9. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
[TBL] [Abstract][Full Text] [Related]
10. DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ; Nguyen Q; Yokota T
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979100
[TBL] [Abstract][Full Text] [Related]
11. The prospects of targeting DUX4 in facioscapulohumeral muscular dystrophy.
Bouwman LF; van der Maarel SM; de Greef JC
Curr Opin Neurol; 2020 Oct; 33(5):635-640. PubMed ID: 32796277
[TBL] [Abstract][Full Text] [Related]
12. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene.
Snider L; Geng LN; Lemmers RJ; Kyba M; Ware CB; Nelson AM; Tawil R; Filippova GN; van der Maarel SM; Tapscott SJ; Miller DG
PLoS Genet; 2010 Oct; 6(10):e1001181. PubMed ID: 21060811
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase A activation inhibits
Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
[TBL] [Abstract][Full Text] [Related]
14. Control of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Cancer.
Karpukhina A; Tiukacheva E; Dib C; Vassetzky YS
Trends Mol Med; 2021 Jun; 27(6):588-601. PubMed ID: 33863674
[TBL] [Abstract][Full Text] [Related]
15. Quantitative proteomics reveals key roles for post-transcriptional gene regulation in the molecular pathology of facioscapulohumeral muscular dystrophy.
Jagannathan S; Ogata Y; Gafken PR; Tapscott SJ; Bradley RK
Elife; 2019 Jan; 8():. PubMed ID: 30644821
[TBL] [Abstract][Full Text] [Related]
16. Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update.
Schätzl T; Kaiser L; Deigner HP
Orphanet J Rare Dis; 2021 Mar; 16(1):129. PubMed ID: 33712050
[TBL] [Abstract][Full Text] [Related]
17. An in silico FSHD muscle fiber for modeling DUX4 dynamics and predicting the impact of therapy.
Cowley MV; Pruller J; Ganassi M; Zammit PS; Banerji CRS
Elife; 2023 May; 12():. PubMed ID: 37184373
[TBL] [Abstract][Full Text] [Related]
18. p38
Rojas LA; Valentine E; Accorsi A; Maglio J; Shen N; Robertson A; Kazmirski S; Rahl P; Tawil R; Cadavid D; Thompson LA; Ronco L; Chang AN; Cacace AM; Wallace O
J Pharmacol Exp Ther; 2020 Sep; 374(3):489-498. PubMed ID: 32576599
[TBL] [Abstract][Full Text] [Related]
19. Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7.
Banerji CRS; Zammit PS
EMBO Mol Med; 2021 Aug; 13(8):e13695. PubMed ID: 34151531
[TBL] [Abstract][Full Text] [Related]
20. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
